Tiedemann Advisors, LLC Gilead Sciences, Inc. Transaction History

Tiedemann Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$61.62 - $67.78 $1.07 Million - $1.18 Million	-17,373 Closed	0 $0
Q3 2019 Nov 06, 2019	BUY	$62.51 - $69.0 $1.09 Million - $1.2 Million	17,373 New	17,373 $1.1 Million
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $927,714 - $1.21 Million	-15,324 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $855 - $947	-12 Reduced 0.08%	15,324 $1.18 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $320,507 - $373,859	4,940 Added 47.52%	15,336 $1.09 Million
Q1 2018 May 11, 2018	BUY	$72.84 - $88.8 $757,244 - $923,164	10,396 New	10,396 $784,000
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $252,084 - $295,911	-3,543 Closed	0 $0
Q3 2017 Nov 28, 2017	SELL	$72.11 - $85.47 $1.75 Million - $2.07 Million	-24,226 Reduced 87.24%	3,543 $281,000
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $661,897 - $784,529	9,179 Added 49.38%	27,769 $1.74 Million
Q2 2017 Aug 14, 2017	BUY	N/A	18,590	18,590 $1.32 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Tiedemann Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Tiedemann Advisors, LLC with notifications on news.